Exercise Intervention Has Biological Effect in Lynch Syndrome
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 25, 2023 -- An exercise intervention has biological effects on the immune system among patients with Lynch syndrome (LS), according to a study published online Sept. 19 in Clinical Cancer Research.
Nan Deng, from The University of Texas MD Anderson Cancer Center in Houston, and colleagues examined the impact of a 12-month aerobic exercise cycling intervention in the biology of the immune system in 21 LS patients. The effects of the exercise program that included cycling classes three times per week for 45 minutes were examined on cardiorespiratory fitness, circulating and colorectal-tissue biomarkers, gene expression, and spatial transcriptomics.
The researchers found that the primary outcome of the exercise intervention was a significant increase in oxygen consumption, while the secondary outcomes included decreases in inflammatory markers (prostaglandin E) in the colon and blood in the exercise versus usual care group. The exercise group also had an increase in the colonic mucosa levels of natural killer and CD8+ T cells in gene expression profiling and spatial transcriptomics on available colon biopsies, which were confirmed by immunohistochemical studies.
"It can be difficult for patients to commit to taking a pill," lead author Eduardo Vilar-Sanchez, M.D., Ph.D., also from the MD Anderson Cancer Center, said in a statement. "If we are able to validate the preventive benefits of this approach in future studies, we hope to offer a 'lifestyle prescription' and give LS patients a new way to possibly lower their cancer risk over time."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.